Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cmi.2021.04.018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Repurposing FDA-Approved Drugs for Eumycetoma Treatment: Homology Modeling and Computational Screening of CYP51 Inhibitors.
Int J Mol Sci
January 2025
Department of Pharmaceutics, College of Pharmacy, Jouf University, Sakaka 72388, Saudi Arabia.
Eumycetoma, a chronic fungal infection caused by , is a neglected tropical disease characterized by tumor-like growths that can lead to permanent disability and deformities if untreated. Predominantly affecting regions in Africa, South America, and Asia, it imposes significant physical, social, and economic burdens. Current treatments, including antifungal drugs like itraconazole, often show variable efficacy, with severe cases necessitating surgical intervention or amputation.
View Article and Find Full Text PDFDirect 16S/ITS rRNA Gene PCR Followed by Sanger Sequencing for Detection of Mycetoma Causative Agents in Dakar, Senegal: A Pilot Study Among Patients with Mycetoma Attending Aristide Le Dantec University Hospital.
Mycopathologia
September 2024
IHU Méditerranée Infection, 19-21 Boulevard Jean Moulin, 13005, Marseille, France.
Article Synopsis
- Mycetoma is a type of infection caused by fungi or bacteria, and identifying the specific agent is crucial for treatment success.
- This study analyzed 32 mycetoma samples from patients, using advanced genetic techniques to identify the pathogens, focusing on different regions of DNA for various grain types.
- The findings revealed a 59.4% identification success rate, with the fungal pathogen Madurella mycetomatis being the most common, and two potential new agents were also discovered.
Emerging therapeutics: The imidazo[1,2-b]pyridazine scaffold as a novel drug candidate for eumycetoma, a neglected tropical disease.
Eur J Med Chem
November 2024
EA 7502 Synthèse et Isolement de Molécules Bioactives (SIMBA), University of Tours, France. Electronic address:
Article Synopsis
- * Current treatments for eumycetoma, largely relying on antifungal drugs and surgery, have low success rates and high chances of relapse.
- * Researchers have synthesized 47 new chemical compounds that show better effectiveness and lower toxicity than existing treatments, particularly one compound that performed similarly to the standard drug itraconazole, suggesting they could be safer options for treating eumycetoma.
Two dose levels of once-weekly fosravuconazole versus daily itraconazole in combination with surgery in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial.
Lancet Infect Dis
November 2024
Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland.
Background: Eumycetoma is an implantation mycosis characterised by a large subcutaneous mass in the extremities commonly caused by the fungus Madurella mycetomatis. Despite the long duration of treatment, commonly a minimum of 12 months, treatment failure is frequent and can lead to amputation. We aimed to compare the efficacy of two doses of fosravuconazole, a synthetic antifungal designed for use in onychomycosis and repurposed for mycetoma, with standard-of-care itraconazole, both in combination with surgery.
View Article and Find Full Text PDFEumycetoma causative agents: A systematic review to inform the World Health Organization priority list of fungal pathogens.
Med Mycol
June 2024
Department of Infectious Diseases, The Alfred and Monash University, Melbourne, Victoria, Australia.
The World Health Organization, in response to the growing burden of fungal disease, established a process to develop a fungal priority pathogens list. This systematic review aimed to evaluate the epidemiology and impact of eumycetoma. PubMed and Web of Science were searched to identify studies published between 1 January 2011 and 19 February 2021.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!